loader2
Partner With Us NRI

Company details

558.00
564.40
557.00
999.00
6M Return -21.08%
1Y Return -31.40%
Mkt Cap.(Cr) 8,973.10
Volume 13,129
Div Yield 0.89%
OI
-
OI Chg %
-
Volume 13,129

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 4,741.49 Cr FV: 1.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 10,242.99 -5,677.80
LAST 3M 56,850.76 -42,328.78
LAST 6M 86,704.51 -29,865.00
LAST 12M 94,363.43 5,399.93

Information

  • About Company
  • Company Info
  • Listing Info
10.62
50.68%
320.6849
14.42%
16.15%
Description
  • Jubilant Pharma Limited is engaged in the Pharmaceutical sector. The company has its market capitalization worth INR 11,533.55 crore as of 16th April 2021. The company was incorporated in 1978. The company has reported quarterly revenue of INR 828.94 crore at the end of December 2020. This company is listed on the Bombay Stock Exchange (BSE), having the code 530019 and on the National Stock Exchange (NSE) with the symbol JUBLPHARMA. The company is headquartered in Noida. It is a pharmaceutical company that offers products and services across the pharma value chain that includes manufacturing and supply of Allergy Therapy Products, Active Pharmaceutical Ingredients. Jubilant Pharmova Limited is a manufacturer and supplier of active pharmaceutical ingredients, radiopharmaceuticals, solid dosage formulations, advanced intermediates, allergy therapy products and nutritional products. It focuses on catering to unmet medical needs at a very affordable price. Pharmaceuticals, contract R&D providers, and patented new products are the company's three market divisions. Via a network of 49 radio pharmacies in the United States, the organisation produces and distributes radiopharmaceuticals. In Bengaluru and Noida, India, it has established two world-class research centres. Shyam S Bhartia, the company's director, oversees procedures. The company reported record profitability with annual revenue of INR 91544 million during the year, which is up by 0.5% year-on-year. In the same year, the company demerged its LSI (Life Science Ingredients) to create unique entities focused on Pharmaceuticals and LSI businesses. Jubilant Pharmova recorded a splurge of 52% year-on-year growth in quarter three. The CDMO and generics business of the company drove the increase in financials. In 2021, Fitch ratings upgraded Jubilant Pharmova Limited from BB- to BB. The up-gradation is a clear reflection of the improvements in the business profile. As of April 2021, the company announced the completion of safety and absorption studies in healthy human volunteers using a novel oral formulation of Remdesivir. The company entered into a non-exclusive licence agreement with Gilead Sciences Inc., which granted the rights to manufacture register and sell Gilead's Remdesivir in India and 126 other countries. The launch of this oral formulation of Covid medicine is likely to affect the company's growth positively.

Read More

Registered Address

Bhartiagram Gajraula, , Amroha, Uttar Pradesh, 244223

Tel : 91-5924-267200
Email : investors:jubl.com/support:jubl.com
Website : http://www.jubl.com

Registrar

Alankit Assignments Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 530019
NSE Code : JUBLPHARMA
Book Closure Date (Month) :
BSE Group : A
ISIN : INE700A01033

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE